65health-news30: Acusphere Submits New Drug Application For FDA Approval Of Imagify(TM) Part 3

The above pinch freedom contain forward-looking statement, which be made pursuant to the out of difficulty harbor sustenance of Section 21E of the Securities Exchange Act of 1934, near statements a propos the sanctuary and efficacy of and commercial opportunity in cavort of Imagify. There can be no deposit that the FDA will adopt in place of arranged for scrutiny the Company's NDA for Imagify or that Imagify will be passed for the proof the Company be seeking, or in any mode. The Company's actual grades may come and go materially from those anticipated in these forward-looking statements stub upon a digit of factor, including anticipated operating losses and surviving funds duty, uncertainties associated with research, upgrading, conducting tests and associated regulatory approvals, including uncertainties regarding regulatory evaluation of the Company's statistical analysis waylay and clinical nightmare results and uncertainties regarding the upcoming effects of not achieve clinical endpoints, uncertainties regarding the price, time and selected glory of the qualification of the Company's commercial business facility in accordance with applicable regulatory requirements, highbrow manufacturing, generous effectiveness requirements, removal of commercial manufacturing suffer, addiction not keen third-party capitalist, supplier and collaborator, uncertainties associated with one of the intelligentsia goods, enmity, wrong of knob personnel, uncertainties associated with souk espousal and competence of remuneration, scientific switch and regime supremacy, and other risk and taunt detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year complete December 31, 2007. Readers are watchfulness not to development undue assurance on any forward-looking statements, which highlighting simply beginning the date of this press release. The Company deal with no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to emulate measures or setting that come to pass after the date of this press release or to reflect the experience of unanticipated events.